Literature DB >> 19302943

Oxcarbazepine use in paroxysmal kinesigenic dyskinesia: report on four patients.

Kipp L Chillag1, Steven T Deroos.   

Abstract

The paroxysmal dyskinesias are a heterogeneous group of movement disorders. They are distinguished from one another by the mechanism through which abnormal movements are induced. Paroxysmal kinesigenic dyskinesia is the most common subtype, consisting of involuntary dyskinesias induced by purposeful movements. It typically responds favorably to anticonvulsants. This retrospective review describes four unrelated children and adolescents with idiopathic paroxysmal kinesigenic dyskinesia who were treated with oxcarbazepine. Each patient achieved complete resolution of signs with low-dose oxcarbazepine monotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302943     DOI: 10.1016/j.pediatrneurol.2008.09.024

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  5 in total

1.  Difficulties in diagnosis and treatment of Wilson disease-a case series of five patients.

Authors:  Anna Członkowska; Karolina Dzieżyc-Jaworska; Bożena Kłysz; Rędzia-Ogrodnik Barbara; Tomasz Litwin
Journal:  Ann Transl Med       Date:  2019-04

2.  Clinical analysis of nine cases of paroxysmal exercise-induced dystonia.

Authors:  Guoping Peng; Kang Wang; Yuan Yuan; Xuning Zheng; Benyan Luo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-12-28

3.  Use of antiepileptic drugs for hyperkinetic movement disorders.

Authors:  A Siniscalchi; L Gallelli; G De Sarro
Journal:  Curr Neuropharmacol       Date:  2010-12       Impact factor: 7.363

Review 4.  Medical treatment of dystonia.

Authors:  Pichet Termsarasab; Thananan Thammongkolchai; Steven J Frucht
Journal:  J Clin Mov Disord       Date:  2016-12-19

5.  Clinical features of patients with paroxysmal kinesigenic dyskinesia, mutation screening of PRRT2 and the effects of morning draughts of oxcarbazepine.

Authors:  Gang Pan; Linmei Zhang; Shuizhen Zhou
Journal:  BMC Pediatr       Date:  2019-11-14       Impact factor: 2.125

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.